J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval ...
FDA approves J&J’s nasal spray for severe depression as stand-alone treatment
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
India Today on MSN13 天
US FDA approves new nasal spray for depression treatment: All about it
The newly FDA-approved nasal spray called Spravato is being manufactured by Johnson & Johnson's and is a standalone treatment ...
Daily6 天
USFDA nod to Lupin Ipratropium Bromide Nasal Solution for runny nose
Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...
Daily21 小时
Lupin bags tentative USFDA okay for generic HIV Medication
Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food ...
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
Medindia7 天
FDA Approves Esketamine Nasal Spray for Resistant Depression
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
来自MSN12 天
FDA Approves ‘Spravato’ Nasal Spray As A Standalone Depression Treatment
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...